Uğur Şahin, BioNTech CEO (Hannes P Albert/picture-alliance/dpa/AP Images)
November 4, 2024 11:40 AM EST
R&D
Pharma

BioN­Tech says VEGF bis­pe­cif­ic’s PD-L1 tar­get, com­bo plans will be its edge

Ayisha Sharma

News Reporter

BioN­Tech said that its VEGF bis­pe­cif­ic sets it apart from com­peti­tors be­cause of its mech­a­nism and how it plans to in­ves­ti­gate the as­set in com­bi­na­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times